Laser Doppler flowmetry confirmed a reactive hyperemia following tourniquet release. In addition, both the phosphorescence lifetime biosensor and NIR methods suggested that the tissue O 2 content temporarily but significantly exceeded baseline following tourniquet release (p<0.05). We term this phenomenon reactive hyperoxia. This suggests that the O 2 supply transiently exceeds oxygen consumption. Even though tissue O 2 consumption was expected to be elevated following ischemia to repay the O 2 debt developed during occlusion, the elevated O 2 content indicates that the increased consumption is met with an even greater elevated O 2 supply. The NIR spectroscopy and phosphorescence lifetime data are consistent. The phosphorescence lifetime biosensor also demonstrates a more prominent response magnitude in general and a faster response over time (71 secs vs. 143 secs in NIR; p = 0.0053), suggesting that the sensing elements may have gained greater proximity to the blood supply via vascular ingrowth through the porous pHEMA scaffold.
PURPOSE:
We have previously shown that human breast adipose-derived stem cells (ASC) from BRCA mutation carriers behave differently from non-mutation carriers in regards to adipocyte differentiation and cytokine production. It is unknown if the BRCA mutation impacts adipose tissue in a manner that promotes breast cancer. In this study we further investigate the effects that BRCA mutations have on the interaction between ASCs and breast cancer cells.
METHODS:
BRCA1-knockout ASCs were generated using CRISPR/Cas9 system in commercially available human ASC lines. BRCA1 protein expression was assessed with Western blots. Next, conditioned medium was generated using ASC groups with and without BRCA1 knockdown. ASC conditioned media was added to MDA-MB-231/Luciferase cell lines (Luciferase-labeled triple negative breast tumor cell lines). Cancer cell proliferation was evaluated using luciferase assays. Scratch assays were used to monitor migration in MDA-MB-231 cells incubated in ASC conditioned media. In parallel studies, human breast primary ASC lines from our repository were also evaluated (n=8, 2 patients with BRCA1 deleterious mutations, 2 patients with BRCA1 intron mutation or mutation without clinical significance, 1 patient with BRCA2 mutation, and 3 patients without genetic mutations). The luciferase assay and scratch assay were repeated using patient samples.
RESULTS:
Using CRISPR/Cas9-mediated methods, we were able to generate effective BRCA1 knockdown in human ASCs, as demonstrated by Western blot. Conditioned media from BRCA1 knockdown ASCs did not significantly alter MDA-MB-231 cell proliferation in comparison to control ASCs (data not shown). However, MDA-MB-231 cells incubated in BRCA1 knockout ASC conditioned media showed significantly higher tumor migration rate in comparison to control ASCs. Conditioned media from our human breast ASC lines with BRCA1 deleterious mutations also demonstrated increased cell migration in 24 hours in vitro (p<0.00001). This effect was not observed for either BRCA1 intron mutations or BRCA2 mutations.
CONCLUSIONS:
We demonstrate here for the first time that human adipose-derived stem cells with BRCA1 mutations have the potential to increase breast tumor cell migration. This is true in both CRISPR/Cas9-mediated BRCA1 knockdown cell lines and in patient samples possessing the BRCA1 deleterious mutation.
